Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors for Uricosuria Authors: Eunjin Bae Published: 2025 ABSTRACT Clinical trials have found that sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce serum urate levels by 0.6–1.5 mg/dL, which might contribute to cardiovascular protection. Urate is the final degradation product of purine nucleotides in humans who lack uricase, unlike most mammals. Thus, the processes of urate handling differ. This review aims to address the handling of urate in humans and the mechanisms through which SGLT2 inhibitors reduce serum urate levels. The kidneys and intestines are respectively responsible for excreting 70% and 30% of urate in humans. Medications that inhibit urate excretion, as well as increased purine intake or production, can cause hyperuricemia and decrease kidney function, which plays a key role in urate excretion. Hyperuricemia is significantly associated with gout, renal stones, mortality, and cardiovascular and chronic kidney diseases. SGLT2 inhibitors lower serum urate by inhibiting its reabsorption through urate anion exchanger 1 in apical membranes of renal proximal tubules and promoting urate excretion through ATP-binding cassette subfamily G member 2 (ABCG2) located in the apical membrane of the proximal tubule and ABCG2 in the intestinal membrane. Further mechanistic studies are needed to elucidate how SGLT2 inhibitors lower serum urate levels. Although the clinical benefits of SGLT2 inhibitors probably do not arise solely from urate reduction, they decrease serum urate levels, suggesting that they could serve as adjunctive therapy for patients with hyperuricemia. URATE METABOLISM AND RENAL PROCESSING Urate is the end product of purine nucleotide degradation in humans. Humans obtain purine nucleotide from three main sources: endogenous synthesis in tissues such as the liver, intestines, and muscle, kidney, and vascular endothelial cells; nucleolysis, which is produced by the breakdown of DNA, RNA, and ATP; and dietary intake. Approximately 80–90% of urate is derived from endogenous metabolism (70–80% is nucleolysis, and 20–30% is endogenous synthesis). The remaining 10–20% is derived from dietary intake [1]. The purine nucleotides adenosine monophosphate (AMP) and guanosine monophosphate are broken down by several enzymes that generate urate as the final product. Two-thirds of urate is excreted through the kidney, and one-third is eliminated through the gastrointestinal tract [2]. Urate is filtered almost freely at the glomerulus, and ~99% is reabsorbed into the blood in the early renal proximal tubule. Although most other mammals convert urate to more soluble allantoin, humans and other primates have higher serum urate levels due to the absence of uricase. Furthermore, the composition of the urate transporter in the kidney differs between humans and rodents [2]. This review aims to elucidate the handling of urate in humans. Fig. 1 shows more details on the handling of urate in the kidney. Urate filtered at the glomerulus is reabsorbed from the lumen into cells of the renal proximal tubule through urate anion exchanger 1 (URAT1) encoded by SLC22A12, on the apical membrane of the proximal tubule, and anions are exchanged and exported to the lumen through an electrochemical gradient [3]. This reabsorption process involves organic anion transporter (OAT) 4, encoded by SLC22A11, on the apical membrane of the proximal tubule. Urate is reabsorbed from cells into the blood via the facilitated diffusion of glucose transporter 9 (GLUT9), encoded by SLC2A9 in the basolateral membrane of the proximal tubule. Mechanisms of urate reabsorption and excretion in proximal tubules of kidneys and involved transporters. Urate is reabsorbed from lumen into renal tubule cells via URAT1 and OAT4 on apical membranes of proximal tubules, then from these cells into interstitial space (blood) via GLUT9a on basolateral membranes. Urate is excreted from blood and transported into renal tubular cells by OAT1/3 on basolateral membranes of proximal tubules, and from cells into lumen through ABCG2, MRP4, and NPT 1/4 on apical membrane. ABCG2, ATP-binding cassette subfamily G member 2; GLUT9a, glucose transporter 9 isoform 9a; MRP4, multidrug resistance-associated protein 4; NPT1, sodium-dependent phosphate transporter 1; NPT4, sodium-dependent phosphate transporter 4; OAT, organic anion transporter; URAT1, urate transporter 1. In the proximal tubule, urate is transported from blood into the cells via OAT1 and 3 respectively encoded by SLC22A6 and SLC22A8, on the basolateral membrane of this tubule. Urate is then excreted into the lumen through sodium-phosphate transporter (NPT) 1 encoded by SLC17A1, NPT4 encoded by SLC17A3, and ATP-binding cassette subfamily G member 2 (ABCG2) located apical membrane of the proximal tubule [234]. Serum urate is transported to intestinal epithelial cells and secreted into the lumen by ABCG2 expressed on the apical membrane of intestinal epithelial cells [5]. The excreted urate is broken down by intestinal microorganisms in the feces. The intestinal microbiota contributes to urate degradation via uricolytic Bacillus and Lactobacillus, which express uricase [6]. A reduction in uricolytic bacteria leads to dysbiosis associated with elevated serum urate [7]. The intestinal excretion of urate that usually accounts for ~30% increases when kidney function declines. Polymorphisms in numerous urate transporters contribute to inter-individual differences in urate processing in humans. Loss-of-function variants in SLC22A12 (URAT1) can cause renal hypouricemia and significantly increase urinary urate excretion [8]. Variants of SLC2A9 which encodes GLUT9 can also significantly affect serum urate levels by 1.2–6.0% [9]. Common variants in ABCG2, such as Q141K, reduce intestinal urate excretion and elevate serum urate [10]. These results indicate that transporter genetics contribute to inter-individual variability in urate homeostasis. MECHANISMS OF HYPERURICEMIA AND ITS CLINICAL IMPLICATIONS Urate is a weak acid (pKa, 5.75) and its form depends on pH. At physiological pH, urate exists predominantly in its ionized form and acts as an antioxidant in human plasma by scavenging reactive oxygen species and protecting against oxidative damage [11]. Monosodium urate crystallizes due to low water solubility when urate levels in plasma or tissue fluid exceed the average solubility limit of 6.8 mg/dL [3]. These crystals can lead to immune response activation, inflammation, gout, and kidney stones. Furthermore, elevated urate levels can exert pro-oxidant and pro-inflammatory effects by increasing oxidative stress, impairing endothelial nitric oxide signaling, and activating inflammasome pathways. These actions contribute to vascular and metabolic dysfunction [1213]. Hyperuricemia is defined as serum urate > 7.0 and > 6.0 mg/dL in men and women, respectively, during excessive urate production or reduced excretion (Table 1). A diet rich in purine or fructose contributes to urate production. Ethanol increases ATP breakdown, which increases purine breakdown and consequent urate production. Urate production is increased in leukemia, lymphoma, and tumor lysis syndrome, which have increased cell turnover, and sometimes, in Lesch–Nyhan syndrome, which causes excessive purine synthesis due to a deficiency of hypoxanthine-guanine phosphoribosyl transferase that is involved in the purine salvage pathway. Hyperuricemia is particularly likely to develop in patients with chronic kidney disease (CKD). Reduced kidney function plays a crucial role in urate excretion, and drugs such as aspirin, loop diuretics, thiazides, cyclosporin, tacrolimus, pyrazinamide, ethambutol, angiotensin-converting enzyme inhibitors, and beta-blockers inhibit urate excretion. Table 1Mechanisms of hyperuricemiaMechanismExamples or related conditionsOverproductionHigh purine or fructose intakePurine-rich diet, fructose-rich beveragesEnhanced ATP degradation and purine catabolismAlcohol (ethanol) increases ATP degradationIncreased cell turnoverLeukemia, lymphoma, tumor lysis syndromeIncreased de novo purine synthesis (enzyme defect)Lesch–Nyhan syndromeUnderexcretionReduced kidney functionChronic kidney diseaseDrug-induced inhibition of uric acid excretionAspirin, loop diuretics, thiazides, cyclosporine, tacrolimus, pyrazinamide, ethambutol, ACE inhibitors, beta-blockersACE, angiotensin-converting enzyme; ATP, adenosine triphosphate. Mechanisms of hyperuricemia ACE, angiotensin-converting enzyme; ATP, adenosine triphosphate. Hyperuricemia is associated with increased cardiovascular mortality and all-cause mortality and is significantly associated with cardiovascular disease [14] such as coronary heart disease, myocardial infarction, and stroke [15], heart failure [16], hypertension [17], atrial fibrillation [18], as well as CKD [1419], renal stone, and gout [19]. Although hyperuricemia is generally associated with poor clinical outcomes, serum urate levels within the physiological range act as a compensatory antioxidant factors in neurodegenerative states, such as Parkinson’s disease [20] and cognitive impairment [21]. This raises the question of whether urate is an independent risk factor for poor clinical outcomes or simply a marker reflecting pathophysiological conditions. Whether lowering urate can reduce risk of cardiovascular disease, hypertension, and CKD progression via urate-lowering therapy has been investigated. A meta-analysis of randomized controlled trial results among patients with gout found that urate-lowering therapy did not reduce the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke [22]. Urate-lowering therapy as an antihypertensive agent is not supported by evidence [23]. Reducing urate does not improve all-cause mortality and cardiovascular death in patients with heart failure [24] or significantly reduce estimated glomerular filtration rates among patients with CKD [25]. Although a conclusion remains difficult, urate serves as a marker reflecting pathophysiological conditions rather than as an independent risk factor. Therefore, maintaining serum urate levels within the physiological range is important. If the level is abnormal, efforts should be made to identify and correct the underlying causes. SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS AND URATE TRANSPORTERS SGLT2 inhibitors inhibit SGLT2 protein in the S1 segments of renal proximal tubules. Approximately 90% of the glucose and Na+ filtered by the glomerulus is reabsorbed by SGLT2. Blocking this process allows SGLT2 inhibitors to lower blood glucose levels [26]. Although SGLT2 inhibitors were originally developed as antidiabetic agents, they also protect the kidney and heart via natriuretic effects, reduced blood pressure, and suppressed glomerular hyperfiltration caused by afferent arteriolar constriction [272829]. SGLT2 inhibitors also reduce serum urate by ~0.5 mg/dL in humans [30]. Among these inhibitors, empagliflozin is the most effective, having reduced urate by 1.12 and 0.43 mg/dL in the EMPEROR-Reduced and exploratory EMPA-KIDNEY trials, respectively [3132]. Dapagliflozin and canagliflozin reduce urate by 0.51–0.84 mg/dL [333435] and 0.39–0.69 mg/dL [3536], respectively, but ertugliflozin and sotagliflozin were less effective (0.23–0.26 mg/dL) [3037]. Although the extent of urate-lowering effect varies according to drugs and underlying diseases, SGLT2 inhibitors actually do reduce urate levels (Table 2). Table 2Effects of SGLT2 inhibitors on serum UA from major clinical or meta-analysis studiesDrugStudy/AnalysisParticipantsChange in serum UAEmpagliflozinEMPEROR-Reduced trial [31]Heart failure and reduced ejection fraction1.12 ± 0.04 mg/dLExploratory analysis of EMPA-KIDNEY trial [32]CKD (eGFR ≥ 20 but < 45 mL/min/1.73 m2 or eGFR ≥ 45 but < 90 mL/min/1.73 m2 with a urinary albumin creatinine ratio ≥ 200 mg/g)0.43 mg/dLMeta-analysis [30]0.77 mg/dLDapagliflozinSingle-center retrospective [33]CKD stage 3–50.8 mg/dLPost-hoc analysis of DAPA-HF [34]Heart failure and reduced ejection fraction0.84 mg/dLMeta-analysis [35]0.51–0.70 mg/dLCanagliflozinPost-hoc analysis of CANVAS Program [36]Type 2 DM and an elevated risk of cardiovascular disease with an eGFR ≥ 30 mL/min/1.73 m2 0.39 mg/dLMeta-analysis [35]0.61–0.69 mg/dLErtugliflozinPost-hoc analysis of VERTIS CV trial [37]Type 2 DM and established ASCVD with an eGFR ≥ 30 mL/min/1.73 m2 0.26 mg/dLSotagliflozinMeta-analysis [30]0.23 mg/dLOverall SGLT2 inhibitorsMeta-analysis and observational studies [30]0.54 mg/dLASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; SGLT2i, sodium-glucose cotransporter 2 inhibitors; UA, uric acid. Effects of SGLT2 inhibitors on serum UA from major clinical or meta-analysis studies ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; SGLT2i, sodium-glucose cotransporter 2 inhibitors; UA, uric acid. The first mechanism through which SGLT2 inhibitors lower serum urate is by blocking SGLT2 in the proximal tubule, which increases glucose and sodium delivery to downstream tubules. Glucosuria and natriuresis augment tubular flow, which dilutes luminal urate and leads to downregulated URAT1, which enhances urinary urate excretion (Fig. 2) [4383940]. A review [4] and a preclinical proteome analysis [38] have shown that SGLT2 inhibitors significantly decrease expression of the SLC22A12 (URAT1 protein-encoding) in the proximal tubules of wild-type mice [39]. SGLT2 inhibitors increase the fractional excretion of urate in patients with type 2 diabetes mellitus, and that pharmacological blockade of URAT1 using benzbromarone attenuated the urate excretion effect of SGLT2 inhibitors [40]. Preclinical data have found that SGLT2 inhibitors increase urate excretion by inhibiting GLUT9 and URAT1 functions [41]. However, the uricosuric effect of SGLT2 inhibitors might be dependent on URAT1, while GLUT9 may be dispensable [42]. Therefore, the uricosuric effects of SGLT2 inhibitors via GLUT9 require further investigation and cannot be definitively concluded. Mechanisms and transporters involved in lowering urate induced by SGLT2 inhibitors. SGLT2 inhibitors block URAT1 on apical membranes of renal proximal tubules, preventing urate reabsorption. Activated ABCG2 on the apical membranes of renal proximal tubules and intestinal epithelial cells promotes urate excretion. ABCG2, ATP-binding cassette subfamily G member 2; SGLT2, sodium-glucose cotransporter 2; URAT1, urate transporter 1. The secretion of urate from the proximal tubule and intestinal epithelial cells into the lumen is mediated by ABCG2 (Fig. 2). A loss of ABCG2 function reduces intestinal urate excretion, leading to elevated serum urate levels in mice [5]. Intestinal urate secretion in humans in vivo is mediated by ABCG2 and polymorphisms that reduce ABCG2 function result in elevated serum urate [43]. In addition, preclinical findings of a rat model of CKD have shown increased intestinal ABCG2 expression under conditions of reduced renal urate excretion [44]. SGLT2 inhibitors might also upregulate ABCG2, thus promoting urate secretion [45]. Although the exact mechanism is unknown, SGLT2 inhibitors enhance cellular antioxidant defenses by increasing intracellular ATP consumption, which leads to AMP accumulation and subsequent AMP-activated protein kinase (AMPK) activation. This promotes the nuclear translocation of Forkhead Box Protein O3 and Nuclear factor erythroid 2-related factor 2 (Nrf2) [4647]. Activated AMPK and Nrf2 signaling can upregulate the urate efflux transporter ABCG2, which increases renal and intestinal urate excretion [45]. However, evidence supporting ABCG2 upregulation and its mechanism by SGLT2 inhibitors is either preclinical [4546] or a review [47]. Therefore, they have limitations that warrant further investigation in humans. Whether SGLT2 inhibitors can improve the unfavorable clinical outcomes associated with hyperuricemia by lowering urate levels awaits further investigation. SGLT2 inhibitors significantly reduce serum urate levels, the risk of gout [48], renal stones [49], cardiovascular disease and hospitalization for heart failure, and kidney disease progression. However, using SGLT2 inhibitors to lower urate as a primary outcome has not been investigated, so a causal relationship between the beneficial effects of SGLT2 inhibitors and urate-lowering has not been established. Furthermore, clear evidence that lowering urate improves outcomes is currently insufficient. Taken together, current outcomes suggest that the clinical benefits of SGLT2 inhibitors probably do not arise solely from lowering urate. However, we reviewed how SGLT2 inhibitors lower urate and identified other metabolic or renal benefits that are associated with decreasing urate levels. Therefore, SGLT2 inhibitors could serve as adjuvant therapy for patients with hyperuricemia. In conclusion, SGLT2 inhibitors lower serum urate levels through numerous interconnected mechanisms, including increased urate excretion, ABCG2, and URAT1. However, the precise mechanism remains unknown, and further investigation is needed.